NanoImaging Services and Proteos Launched TrueCourse Biosciences
The newly formed contract research organization offers integrated validation services for AI-designed drug discovery.
Updated on Sept. 22, 2026 in Biotech

Live Poll
Do you trust that AI-designed drugs are as safe and effective as traditional drug discovery methods?
NanoImaging Services and Proteos have launched TrueCourse Biosciences, an integrated contract research organization designed to validate AI-generated drug models. The company uses structural biology and biophysical assays to support pharmaceutical development.
Why it matters
The company was established to provide critical validation services for AI-driven drug discovery, addressing the need for experimental verification of computational models. By combining multiple technical capabilities, it aims to streamline the development process for modern therapeutics.
TrueCourse Biosciences integrates specialized capabilities in protein production, BLI, SPR, cryo-EM, X-ray crystallography, and nanoparticle characterization. These tools are applied to validate AI-generated drug models through structural biology and biophysical assays.
The players
Dr. Lindsey Gottler
She serves as the Chief Executive Officer of TrueCourse Biosciences and previously worked as the Chief Scientific Officer at Proteos.
Dr. Giovanna Scapin
She currently serves as the Chief Scientific Officer at TrueCourse Biosciences.
NanoImaging Services
This company is a founding partner of TrueCourse Biosciences that provides specialized imaging and characterization expertise.
Proteos
This organization is a founding partner of TrueCourse Biosciences that contributes protein production capabilities to the joint venture.
The details
The firm operates facilities in California, Massachusetts, and Michigan to support its multidisciplinary research efforts. It combines the existing expertise of its parent organizations to offer a unified pipeline for testing and refining drug candidates.
Timeline
The launch of TrueCourse Biosciences was formalized in September 2026.
The Tech Race
The launch of TrueCourse Biosciences reflects a broader trend of integrating biophysical validation tools to support the rapid output of AI-driven drug discovery programs. This consolidation marks a shift from fragmented service models toward end-to-end platforms that address the limitations of computational modeling.
The formation of this organization could accelerate the timeline for drug development by providing faster, more reliable verification of AI-designed therapeutic models. Researchers and developers may find more efficient workflows for characterization as the company expands its service scope.
The takeaway
The successful integration of structural biology and AI models is becoming a critical hurdle in modern pharmaceutical research. Companies that offer streamlined validation services will likely play a central role in translating computational designs into viable clinical treatments.
Further reading
Learn more about the latest innovations in Biotech.
Live Poll
Do you trust that AI-designed drugs are as safe and effective as traditional drug discovery methods?






